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Risk of 30-day Readmission After Knee or Hip Replacement in 
Rheumatoid Arthritis and Osteoarthritis by Non-Medicare and 
Medicare Payer Status
Ali Yazdanyar1, Anthony Donato2, Mary Chester Wasko3, and Michael M. Ward4
ABSTRACT. Objective. To determine the indication and risk of 30-day rehospitalization after hip or knee replacement 
among patients with rheumatoid arthritis (RA) and osteoarthritis (OA) by Medicare and non-Medicare 
status.
 Methods. Using the Nationwide Readmission Database (2010–2014), we defined an index hospitalization 
as an elective hospitalization with a principal procedure of total hip (THR) or knee replacement (TKR) 
among adults aged ≥ 18 years. Primary payer was categorized as Medicare or non-Medicare. Survey logistic 
regression provided the odds of 30-day rehospitalization in RA relative to OA. We calculated the rates for 
principal diagnoses leading to rehospitalization.
 Results. Overall, 3.53% of 2,190,745 index hospitalization had a 30-day rehospitalization. Patients with RA 
had a higher adjusted risk of rehospitalization after TKR (OR 1.11, 95% CI 1.02–1.21) and THR (OR 1.39, 
95% CI 1.19–1.62). Persons with RA and OA did not differ with respect to rates of infections, cardiac events, 
or postoperative complications leading to the rehospitalization. After TKR, RA patients with Medicare had 
a lower venous thromboembolism (VTE) risk (OR 0.58, 95% CI 0.58–0.88), whereas those with RA had a 
greater VTE risk (OR 2.41, 95% CI 1.04–5.57) after THR.
 Conclusion. Patients with RA had a higher 30-day rehospitalization risk than OA after TKR and THR 
regardless of payer type. While infections, postoperative complications, and cardiac events did not differ, 
there was a significant difference in VTE as the principal diagnosis of rehospitalization. 
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Joint replacement is cost effective and associated with improve-
ments in quality of life, function, and patient satisfaction.1,2,3,4 It 
serves as an alternative when medical interventions are no longer 
alleviating symptoms. Such is the case for patients with severe 
joint damage resulting from end-stage osteoarthritis (OA) or 
rheumatoid arthritis (RA) with poor response to medications, 
resulting chronic synovitis and progressive erosive arthritis.
 Several adverse events potentially requiring rehospital-
ization after total joint replacement surgery include infec-
tions,5,6,7,8 cardiovascular events,9,10 venous thromboembolism 
(VTE),11,12,13,14 and mortality.15,16,17 Current literature on read-
mission rates after major joint replacement shows high variability 
with respect to the postoperative follow-up time, age, and specific 
underlying joint disease of study populations, as well as the 
number of potential confounders considered and the methods 
for accounting for these.18–29 A number of studies have assessed 
risk after joint replacement among patients with RA.20,22,29,30,31,32 
To date, the majority of studies have either evaluated a 90-day 
follow-up period, or were limited to a single institution or to a 
specific aged population such as Medicare beneficiaries. 
 Using a large population-based sample representative data-
base of US hospitalizations including both non-Medicare and 
Medicare patients, we describe the risk of 30-day rehospitaliza-
tion along with the principal diagnosis for the rehospitalization 
among persons with RA and OA after primary total hip replace-
ment (THR) or total knee replacement (TKR) while accounting 
for comorbid conditions.
METHODS
We conducted a cross-sectional analysis using the 2010–2014 Nationwide 
Readmissions Database (NRD), Healthcare Cost and Utilization Project, 
Agency for Healthcare Research and Quality. NRD databases have been 
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described elsewhere.28,29 Briefly, NRD is a publicly available database that 
includes approximately 28 million annual hospital discharges along with 
linkage variables to allow patient tracking for readmission within the same 
calendar year. As a complex survey design database, it requires the incorpora-
tion of discharge-level weights to generate national estimates. Additionally, 
in the calculation of standard errors it requires the data elements of strati-
fication and clusters. The NRD, a limited dataset, is not subject to HIPAA 
(US Health Insurance Portability and Accountability Act) review by an 
institutional review board.30
 We defined an index admission as an elective hospitalization among 
persons aged ≥ 18 years including a principal procedure of primary THR 
or primary TKR, who were alive at discharge. Excluded were hospitaliza-
tions in the month of December in order to ensure a 30-day postdischarge 
follow-up period since linkage across calendar years is not possible. The 
International Classification of Diseases, 9th revision, Clinical Modification 
(ICD-9-CM) codes were used to extract the principal procedure and diag-
noses in the index hospitalization along with the principal diagnosis for 
the rehospitalization. Principal procedures of primary THR (81.51), TKR 
(81.54), along with diagnoses of RA (714), OA (715), and comorbid con-
ditions, were extracted using their ICD-9-CM codes. Patients were cat-
egorized as RA if both RA and OA diagnoses were present. The primary 
payer for the index hospitalization was categorized as either Medicare or 
non-Medicare, where non-Medicare included Medicaid, private insurance, 
self-pay, no charge, or other payer.
 The main outcome of interest was a 30-day rehospitalization defined as 
the first rehospitalization within a 30-day time period after discharge from 
the index hospitalization. We considered the reason for the 30-day rehospi-
talization to be represented by the principal diagnosis listed. The principal 
diagnoses of primary interest included cardiac events, strokes, VTE, infec-
tions, acute renal failure, and postprocedural complications (Supplementary 
Table  1, available from the authors on request). Briefly, cardiac diagnoses 
included acute coronary syndrome, acute myocardial infarction, acute con-
gestive heart failure (CHF), and dysrhythmias. VTEs included diagnoses 
of deep VTE or pulmonary embolism. Infections were categorized as either 
localized or distant to the surgical site. Infections localized to the surgical 
site consisted of ICD-9-CM diagnoses including an infection and inflam-
matory reaction due to internal joint prosthesis (996.66) or other postop-
erative infection (998.59). Infections not localized to the surgical site were 
referred to as distant infections and included sepsis, pneumonia, superfi-
cial infections of the skin and abscesses, or infections involving the upper 
or lower genitourinary tract. Postprocedural complications were extracted 
using ICD-9-CM codes 998 and 996 (Supplementary Table 1). For example, 
a dislocation of prosthetic joint was identified by using ICD-9-CM 996.42 
and a hematoma complicating a procedure by using ICD-9-CM 998.12. We 
defined a composite event as the occurrence of a cardiac event, stroke, VTE, 
infection, acute renal failure, or a postprocedural complication.
Statistical analysis. Categorical variables were expressed as weighted fre-
quencies (±  standard error [SE]) and percentages. Continuous variables 
were expressed as means (±  SE). The Rao-Scott chi-square test was used 
to test the association between the categorical variables. Survey logistic 
regression provided the odds of outcomes among persons with RA relative 
to OA. The regression models included an unadjusted model (Model  1); 
Model 1 plus age and sex (Model 2); and Model 2 plus comorbid condi-
tions including coronary artery disease, hypertension, diabetes mellitus 
(DM), chronic kidney disease, chronic pulmonary disease, chronic CHF, 
and cancer (Model 3). All statistical tests were based on a 2-sided test with 
a significance level of 0.05 and accounted for the survey design features of 
NRD in order to provide population-based estimates. All statistical analyses 
were conducted using SAS statistical software (SAS Institute Inc.).
RESULTS
There were 2,190,745 index hospitalizations for TKR or THR 
of which 67,059 were persons with RA and 2,123,686 with OA 
(Supplementary Table 2, available from the authors on request). 
Persons with RA were younger (64.38 ± 0.10 vs 65.79 ± 0.06 
yrs, P < 0.001) and more likely to be female (75.59% vs 59.62%, 
P < 0.001), have coexisting conditions of chronic CHF (2.57% 
vs 1.93%, P < 0.001), and have chronic obstructive pulmonary 
disease (COPD; 19.17% vs 14.13%, P < 0.001), while less likely 
to have hypertension (HTN; 64.27% vs 65.36%, P = 0.003).
 A total of 2,184,477 (99.7%) of the 2,190,745 index 
hospitalizations had nonmissing payer information including 
1,207,899 (55.29%) with Medicare and 976,578 (44.71%) with 
non-Medicare (Table 1). Among the non-Medicare hospitaliza-
tion, persons with RA were less likely than those with OA to 
have coronary artery disease (CAD; 4.20% vs 4.71%, P = 0.04), 
DM (15.99% vs 16.92%, P = 0.04), but more likely to have CHF 
(1.41% vs 0.91%; P =0.0001) and COPD (16.81% vs 13.04%, 
P < 0.0001). Among the Medicare hospitalizations, persons with 
RA were less likely than those with OA to have HTN (69.3% vs 
71.6%, P < 0.0001), CAD (9.45% vs 10.19%, P = 0.01), DM 
(20.48% vs 21.95%, P = 0.0002), but more likely to have CHF 
(3.37% vs 2.75%, P = 0.0003), and COPD (20.77% vs 15.02%, 
P < 0.001). A significantly greater proportion of patients with 
RA were aged < 65 years as compared to those with OA in the 
Medicare group (22.03% vs 10.10%, P < 0.001).
 The principal procedure was THR 513,021 (23.48%) and 
TKR in 1,671,456 (76.52%) hospitalizations. Table  2 and 
Table 3 display patient characteristics by joint replacement type 
among persons with non-Medicare and Medicare, respectively. In 
both types of joint replacement surgeries and payer types, there 
was a higher prevalence of CHF and COPD and lower preva-
lence of HTN among patients with RA. In both non-Medicare 
and Medicare patients who underwent TKR, there was a lower 
prevalence of CAD, HTN, and DM in persons with RA.
Study outcomes. The overall 30-day readmission rate was 77,196 
(3.53%). The readmission rate was higher when comparing 
persons with RA to OA (4.02% vs 3.52%, P  =  0.0003) and 
those with Medicare vs non-Medicare as payer (4.13% vs 2.80%, 
P < 0.0001). The 30-day readmission rate after TKR was 3.55%, 
which did not significantly differ between persons with RA 
and OA among those with non-Medicare (3.12% vs 2.83%, 
P = 0.16) or Medicare (4.26% vs 4.10%, P = 0.47). The readmis-
sion rate after THR was 3.47%. Persons with RA had a higher 
readmission rate after THR among both non-Medicare (3.85% 
vs 2.63%, P = 0.005) and Medicare (5.51% vs 4.16%, P = 0.002) 
payers (data not shown).
 As shown in Table 4, the adjusted OR of 30-day rehospital-
ization after TKR was significantly higher (OR  1.11; 95%  CI 
1.02–1.21) in persons with RA as compared to OA. In analysis 
by payer type, the increased risk was limited to those with 
non-Medicare (OR 1.15, 95% CI 1.00–1.32) and not to those 
with Medicare (OR 1.04, 95% CI, 0.93–1.16). After THR, the 
risk of 30-day readmission was higher among patients with RA, 
a finding which was consistent overall (OR 1.39, 95% CI, 1.19–
1.62) and by non-Medicare (OR 1.45; 95% CI 1.10–1.91) and 
Medicare (OR 1.27, 95% CI 1.05–1.54).
 The study composite event, which included cardiac events, 
strokes, VTEs, infections, acute renal failure, and postprocedural 
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complication as principal diagnoses, accounted for 36,665 
(47.49%) of the 77,196 30-day rehospitalizations, with the 
remaining hospitalizations due to alternate principal diagnoses. 
Patients with RA and OA did not differ in the proportion of 
rehospitalizations due to the composite event (49.7% vs 48.93%, 
P = 0.66).
 The principal diagnosis for the rehospitalization was an infec-
tion in 14,425 (18.69%), a postoperative complication in 11,815 
(17.74%), a VTE event in 5349 (6.93%), and a cardiac diagnosis 
in 3174 (4.11%). Rehospitalizations with an infection, including 
both local and distant to surgical site, as the principal diag-
nosis did not significantly differ between RA and OA (20.97% 
vs 18.60%, P  =  0.09). Infections distant to the surgical site 
occurred in 1579 (4.96%) and those localized to the surgical site 
accounted for 10,598 (13.73%) of the rehospitalizations with 
no significant difference between RA and OA in local (14.51% 
vs 13.70%, P  =  0.50) or distant infections (6.47% vs 4.90%, 
P = 0.06; data not shown). Figure 1 displays the rates of infec-
tions listed as primary indicators for 30-day rehospitalization. 
Regardless of payer type, persons with RA and OA did not differ 
significantly in the rate of local, distant, or overall infections.
 Figure 2 displays the rates of cardiac, VTE, and postopera-
tive complications as the indication for the 30-day rehospital-
ization. There was no significant difference between RA and 
OA in either cardiac events or postoperative complications after 
TKR or THR. After TKR, RA patients with Medicare had a 
Table 1. Characteristics by RA and OA status by insurance type status.
   Non-Medicare, n = 976,578    Medicare, n = 1,207,899 P
  RA OA P  RA OA 
  n = 26,940 n = 949,638  n = 39,919 n = 1,167,980
Age, yrs   < 0.001   < 0.001
 18–64 23,437 (86.99) 808,699 (85.16)  8796 (22.03) 117,911 (10.10) 
 ≥ 65 3503 (13.01) 140,939 (14.84)  31,123 (77.97) 1,050,069 (89.90)  
Female sex 19,926 (73.96) 531,668 (55.99) < 0.001 30,644 (76.77) 731,009 (62.59) < 0.001
Surgery    < 0.001   0.0001
 Hip 5590 (20.75) 237,871 (25.05)  8270 (20.72) 261,290 (22.37) 
 Knee 21,350 (79.25) 711,767 (74.95)  31,649 (79.28) 906,690 (77.63) 
CAD 1131 (4.20) 44,707 (4.71) 0.04 3774 (9.45) 119,011 (10.19) 0.01
CHF 380 (1.41) 8712 (0.91) 0.0001 1343 (3.37) 32,074 (2.75) 0.0003
DM 4310 (15.99) 160,713 (16.92) 0.04 8177 (20.48) 256,330 (21.95) 0.0002
Cancer 56 (0.21) 2583 (0.27) 0.27  186 (0.47) 7105 (0.61) 0.06
HTN 15,287 (56.74) 547,796 (57.68) 0.12 27,677 (69.33) 836,297 (71.60) < 0.0001
CKD 561 (2.08) 18,316 (1.93) 0.31 1973 (4.94) 61,451 (5.26) 0.17
COPD 4528 (16.81) 123,830 (13.04) < 0.0001 8290 (20.77) 175,442 (15.02) < 0.001
VHD 642 (2.38) 18,245 (1.92) 0.01 1598 (4.00) 47,610 (4.08) 0.70
Values are expressed as n (%) unless otherwise indicated. CAD: coronary artery disease; CHF: congestive heart failure; CKD: chronic kidney disease; COPD: 
chronic obstructive pulmonary disease; DM: diabetes mellitus; HTN: hypertension; OA: osteoarthritis; RA: rheumatoid arthritis; VHD: valvular heart disease.
Table 2. Characteristics among non-Medicare patients by type of arthritis and joint replacement. 
  Total Knee Replacement, n = 733,117 P Total Hip Replacement, n = 243,461 P
  RA OA  RA OA 
  n = 21,350  n = 711,767   n = 5590  n = 237,871 
Age, yrs   < 0.001   0.83
 18–64 18,521 (86.75) 599,961 (84.29)  4916 (87.94) 208,738 (87.75) 
 ≥ 65  2829 (13.25) 111,806 (15.71)  674 (12.06) 29,133 (12.25)  
Female sex 16,403 (76.83) 418,614 (58.81) < 0.001 3523 (63.20) 113,054 (47.53) < 0.001
CAD 915 (4.29) 34,627 (4.87) 0.04 215 (3.85) 10,080 (4.24) 0.47
CHF 306 (1.43) 6849 (0.96) 0.002 74 (1.33) 1863 (0.78) 0.03
DM 3609 (16.90) 133,817 (18.80) 0.0002 702 (12.55) 26,896 (11.31) 0.13
Cancer 35 (0.16) 1869 (0.26) 0.13  22 (0.39) 713 (0.30) 0.50
HTN 12,517 (58.63) 429,211 (60.30) 0.02 2770 (49.54) 118,585 (49.85) 0.82
CKD 460 (2.15) 14,712 (2.07) 0.62 101 (1.81) 3604 (1.52) 0.30
COPD 3707 (17.36) 97,191 (13.65) < 0.0001 821 (14.69) 26,639 (11.20) < 0.001
VHD 516 (2.42) 13,954 (1.96) 0.02 126 (2.25) 4291 (1.80) 0.16
Values are expressed as n (%) unless otherwise indicated. CAD: coronary artery disease; CHF: congestive heart failure; CKD: chronic kidney disease; COPD: 
chronic obstructive pulmonary disease; DM: diabetes mellitus; HTN: hypertension; OA: osteoarthritis; RA: rheumatoid arthritis; VHD: valvular heart disease.
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significantly lower rate of VTE as compared to OA (4.2% vs 
7.1%, P  =  0.01), while the difference in VTE events among 
non-Medicare patients did not reach statistical signifi-
cance (5.5% vs 8.7%, P  =  0.06). After THR, in contrast to 
non-Medicare patients, Medicare patients with RA had a 
significantly higher rate of VTE as the principal diagnosis for 
the rehospitalization (9.0% vs 3.9%, P  =  0.03). RA patients 
with Medicare had a lower risk of VTE (OR  0.58; 95%  CI 
0.58–0.88) after TKR, whereas those with RA had a greater VTE 
risk post-THR (OR 2.41, 95% CI 1.04–5.57; data not shown).
DISCUSSION
In this large population-based sample representing US hospi-
talization with a primary THR/TKR, both non-Medicare and 
Table 3. Characteristics among Medicare patients by type of arthritis and joint replacement.
  Total Knee Replacement, n = 938,339 P Total Hip Replacement, n = 269,560 P
  RA OA  RA OA 
  n = 31,649  n = 906,690  n = 8270 n = 261,290 
Age, yrs   < 0.001   < 0.001
 18–64 6965 (22.01) 91,267 (10.07)  1830 (22.13) 26,643 (10.20) 
 ≥ 65  24,684 (77.99) 815,423 (89.93)  6440 (77.87) 234,646 (89.80)  
Female sex 24,607 (77.75) 576,969 (63.63) < 0.001 6037 (72.99) 154,040 (58.95) < 0.001
CAD 3003 (9.49) 92,131 (10.16) 0.04 771 (9.32) 26,879 (10.29) 0.16
CHF 1020 (3.22) 25,034 (2.76) 0.01 323 (3.91) 7040 (2.69) 0.01
DM 6706 (21.19) 210,721 (23.24) < 0.001 1472 (17.80) 45,609 (17.46) 0.68
Cancer 133 (0.42) 5315 (0.59) 0.05 53 (0.64) 1790 (0.69) 0.78
HTN 22,218 (70.20) 658,387 (72.61) < 0.001 5459 (66.01) 177,910 (68.09) 0.03
CKD 1558 (4.92) 48,405 (5.34) 0.11 415 (5.02) 13,046 (4.99) 0.96
COPD 6496 (20.52) 136,797 (15.09) < 0.0001 1794 (21.69) 38,645 (14.79) < 0.001
VHD 1226 (3.87) 36,198 (3.99) 0.56 372 (4.50) 11,412 (4.37) 0.79
CAD: coronary artery disease; CHF: congestive heart failure; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; DM: diabetes 
mellitus; HTN: hypertension; OA: osteoarthritis; PVD: peripheral vascular disease; RA: rheumatoid arthritis; VHD: valvular heart disease.
Table 4. Risk of 30-day readmission and composite adverse events after index hospitalization for primary joint 
replacement.
   Model 1 Model 2 Model 3
Total knee replacement      
 30-day readmission      
 Overall 1.08 (0.99–1.17) 1.14 (1.04–1.24) 1.11 (1.02–1.21)
 By payer type   
  Non-Medicare 1.10 (0.96–1.26) 1.16 (1.01–1.33) 1.15 (1.00–1.32)
  Medicare 1.04 (0.94–1.16) 1.05 (0.94–1.17) 1.04 (0.93–1.16)
Composite event     
  Overall 1.03 (0.87–1.23) 1.07 (0.90–1.27) 1.05 (0.89–1.25)
  By payer type     
  Non-Medicare 1.23 (0.95–1.59) 1.32 (1.02–1.71) 1.31 (1.01–1.70)
  Medicare 0.96 (0.78–1.19) 0.96 (0.78–1.19) 0.95 (0.77–1.17)
Total hip replacement    
 30-day readmission   
 Overall 1.43 (1.23–1.67) 1.45 (1.24–1.70) 1.39 (1.19–1.62)
 By payer type   
  Non-Medicare 1.48 (1.12–1.96) 1.50 (1.13–1.98) 1.45 (1.10–1.91)
  Medicare 1.34 (1.11–1.62) 1.31 (1.09–1.59) 1.27 (1.05–1.54)
 Composite event     
  Overall 1.01 (0.76–1.35) 0.99 (0.74–1.32) 1.00 (0.74–1.33)
  By payer type     
  Non-Medicare 0.91 (0.54–1.55) 0.86 (0.51–1.46) 0.84 (0.50–1.42)
  Medicare 1.07 (0.74–1.55) 1.05 (0.73–1.51) 1.07 (0.74–1.54)
Values are expressed as OR (95% CI). Values in bold are statistically significant. Model 1 = unadjusted model. 
Model 2 = Model 1 plus age and sex. Model 3 = Model 2 plus comorbidities (coronary artery disease, hyper-
tension, diabetes mellitus, chronic kidney disease, chronic pulmonary disease, chronic congestive heart failure, 
cancer).
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Medicare patients with RA were at a greater risk for 30-day 
rehospitalization after THR, and non-Medicare patients with 
RA after TKR, as compared to those with OA. Nearly half of 
the rehospitalizations were due to infections, postoperative 
wound complications, cardiac events, or VTE events. Infections 
accounted for approximately 1 in 5 rehospitalizations. Whereas 
both non-Medicare and Medicare patients with RA had a slightly 
higher rate of rehospitalization with an infection as a principal 
diagnosis after TKR and THR, the difference with patients with 
OA was not statistically significant. The proportion of 30-day 
rehospitalizations with postoperative wound complications or 
cardiac reasons as the etiology after TKR and THR did not 
differ between patients with RA and OA in either the non-Medi-
care or Medicare populations. While Medicare patients with 
RA had a significantly higher risk of VTE events post-THR, 
patients with OA had a higher proportion of readmissions 
due to VTE events after TKR. Overall, patients with RA had 
a higher risk for 30-day rehospitalization than those with OA. 
The increased rehospitalization among patients with RA was not 
due to differences in infections, cardiac events, or postoperative 
complications.
 Rehospitalizations represent a considerable concern 
after major joint surgery. The need for rehospitalization 
within a 30-day time period is of both clinical and economic 
significance.33,34,35 Among Medicare beneficiaries, the 30-day 
readmission rate after major joint replacement has been reported 
to range from 5.9% to 8.5% for the time period of 1991–2008 
and 6.2% for 2006–2015.18,19 Single-center studies that were not 
limited to Medicare beneficiaries reported a 30-day readmission 
rate of 6.2% and 4.4% after primary TKR and THR, respec-
tively.20,21 Studies with a focus on patients with inflammatory 
arthritis (IA) have also reported on the risk for readmission after 
replacement.22,28,31 Singh et al reported arthritis-specific 90-day 
readmission rates after knee or hip replacement to be 8.5% and 
6.7% in persons with RA and OA, respectively.22 Based on an 
age- and sex-matched study population of 768 persons with RA 
and 3940 with OA included in the Taiwan National Health 
Insurance Research Database, Kang et al reported that 90-day 
readmission rates were higher in patients with RA (14.2%) vs 
OA (11.3%).31 Our study provides the 30-day readmission risk 
among persons with RA vs OA after primary joint replacement 
among a nationally representative US study population. In our 
cohort, the crude 30-day readmission rate was 3.5%, which was 
significantly higher among patients with RA than those with 
OA (4.0% vs 3.5%, P = 0.0003). Patients with RA who under-
went primary TKR and THR had an 11% and 39% increase in 
the odds of 30-day rehospitalization, respectively, compared to 
patients with OA.
Figure 1. Infectious indication for 30-day readmission rates for (A) total knee replacement, and (B) total hip 
replacement. * Cell sizes n < 10 not reported as per HCUP reporting recommendations. HCUP: Healthcare Cost 
and Utilization Project; OA: osteoarthritis; RA: rheumatoid arthritis.
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 Infections, including prosthetic joint infections, represent 
a major postoperative concern after joint replacement surgery. 
Factors such as immunosuppressive medications, increased oper-
ating time, hematomas, and surgical site infections, along with 
several comorbid conditions including obesity, malignancy, and 
RA, have been associated with increased risk for prosthetic joint 
infections.36 The association between RA and infections may 
be due to factors such as disease-related altered immune state, 
comorbid conditions, and immunosuppressive treatment regi-
mens including corticosteroids, conventional disease-modifying 
antirheumatic drugs (DMARDs), and biologic DMARDs. 
George et al reported the rate of postoperative hospitalized 
infections occurring within 30 days among Medicare partic-
ipants with RA who underwent elective hip or knee replace-
ment as 9.0%.19 In a matched case-control study, patients 
with RA had 2-fold higher risk of serious infections.37 Among 
patients receiving knee replacement, Stundner et al reported a 
significantly higher rate of infections among persons with RA 
vs OA (4.5% vs 3.8%, P < 0.01).38 As for posthip replacement, 
a higher incidence of sepsis (0.40% vs 0.14%, P < 0.01), pneu-
monia (1.21% vs 0.80%, P  =  0.0036), and all other infections 
(6.32% vs 4.38%, P  <  0.01) was reported in persons with RA 
vs OA.39 In contrast, a study by Michaud et al using data from 
the Veterans Affairs Surgical Quality Improvement Program to 
compare the 30-day postoperative hip and knee replacement 
rate of infections found no significant difference in the infection 
rates (4.17% vs 4.15%, P = 0.97) or in the relative risk between 
the RA and OA groups (OR 1.02, 95% CI 0.72–1.47).40 Our 
study assessed the risk of both local and distant infections at 30 
days after primary TKR and THR. Our findings did not iden-
tify a significant difference between patients with RA and OA 
with respect to the risk of infections, a finding that was consis-
tent among non-Medicare and Medicare patients.
 In addition to infections, other postoperative complications 
such as wound dehiscence, hematomas, and seromas could 
complicate patient recovery. Dislocation, for example, can be a 
potential early complication after hip replacement. The rates and 
contributing factors to postoperative hip dislocation after hip 
replacement have been previously published.32,41,42,43 Dislocation 
rates as high as 11% have been reported after hip replacement,32 
and it is reportedly more common in patients with RA. Ravi et 
al reported that the rate of hip dislocations after hip replacement 
was 2.6% and 1.2% among patients with RA vs OA, respec-
tively.30 Zwartelé et al reported on a risk of dislocation more than 
3-fold greater among those with IA relative to those without.32 
The results of our study did not reveal any significant difference 
Figure 2. Cardiac, VTE, and other postoperative complication indication for 30-day rehospitalization for (A) total 
knee replacement, and (B) total hip replacement. * Cell sizes n < 10 not reported as per HCUP reporting rec-
ommendations. HCUP: Healthcare Cost and Utilization Project; N/A: not applicable; OA: osteoarthritis; RA: 
rheumatoid arthritis; VTE: venous thromboembolism.
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between RA and OA with respect to postoperative complica-
tions, including dislocation of internal joint prothesis, wound 
disruption, postoperative seroma, or hematoma.
 Studies reporting on the risk of VTE among patients with 
RA have been mixed, with some reporting a higher risk while 
others a decreased or similar risk as compared with patients 
with OA.12,44,45,46 We found the rate of VTE events at 30 days 
post-TKR and also among non-Medicare patients who under-
went THR to be lower among patients with RA as compared 
with OA. In contrast, after THR, Medicare patients with RA 
had a higher rate of VTE events as compared with those with 
OA. Several possibilities may account for our findings. First, 
given our need to rely on ICD codes provided in the NRD to 
capture diagnoses, there may have been missed patient character-
istics or diagnoses that could have led to differential outcomes. 
Alternatively, patients with RA may have had greater limitations 
in their mobility before and/or after THR, leading to a greater 
risk of VTE events. There may also have been a differential 
detection bias in the post-THR phase. Last, we could account 
for neither the duration nor the severity of inflammation, either 
in acute or chronic phases, in the patients with RA; this could 
have affected hypercoagulability.
 It is important to highlight several strengths and limitations 
of our study. The main strength of our study is the use of a nation-
ally representative US study population that included patients 
with and without Medicare. Several limitations of our study 
include lack of information on medication use, including immu-
nosuppressives used to treat RA, as well as lack of data on func-
tional status, duration, and severity of RA, and specific details 
regarding the operation such as duration and type of prosthetic 
implant. Since NRD lacks patient identifiers, the possibility of 
multiple index hospitalizations for the same patient undergoing 
primary THR and TKR cannot be excluded.
 In summary, patients with RA are at a significantly higher risk 
for a 30-day rehospitalization after both primary TKR and THR 
surgery in both non-Medicare and Medicare payer populations. 
There was no significant difference between patients with RA 
and OA with respect to infections, postoperative complications, 
or cardiac events within the 30-day follow-up period. However, 
there was a statistically higher rate of VTE as the indication for 
readmission in patients with RA and Medicare.
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